Summary

Aliskiren in addition to standard therapy does not reduce cardiovascular death or heart failure (HF) rehospitalization in patients hospitalized for HF with reduced left ventricular ejection fraction. This article presents data from the Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure trial [ASTRONAUT; Gheorghiade M et al. JAMA 2013].